Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

NCT01169649 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

PANCREAS
Neuroendocrine

Interventions

DRUG: MK-2206

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]